文献速递创伤与烧伤重症综合管理与镇静镇痛

创伤患者预防性低分子肝素抗Xa水平与静脉血栓栓塞症的关系:系统评价与Meta分析

Relationship between anti-Xa level achieved with prophylactic low-molecular weight heparin and venous thromboembolism in trauma patients: A systematic review and meta-analysis.
PubMed 文献 · J Trauma Acute Care Surg · 2022-02-22
一句话结论创伤患者抗Xa水平较高与VTE风险降低相关,剂量调整可提高抗Xa达标率但不减少VTE。

该系统评价与Meta分析纳入24项研究(19项回顾性、5项前瞻性),评估创伤患者预防性低分子肝素抗Xa水平与VTE的关系、剂量调整对达标的改善及与标准剂量的比较。结果:抗Xa达标与VTE风险降低相关(OR 0.52,P=0.03);剂量调整方案中768例(75.3%)达到预防性抗Xa;剂量调整较标准剂量提高抗Xa达标率(OR 4.05,P=0.007),但VTE(OR 0.72,P=0.15)和肺栓塞(OR 0.48,P=0.10)无显著差异;亚组分析剂量调整亦未显著减少VTE(OR 0.68,P=0.08)。结论:抗Xa水平较高者VTE风险较低,抗Xa指导的剂量调整可提高达标率,但可能不减少VTE。

要点

  • 创伤患者预防性低分子肝素后抗Xa达标(峰值≥0.2 IU/mL或谷值≥0.1 IU/mL)与VTE风险降低相关(OR 0.52,P=0.03)。
  • 剂量调整方案中768例(75.3%)患者达到预防性抗Xa水平。
  • 剂量调整较标准剂量提高抗Xa达标率(OR 4.05,P=0.007),但VTE(OR 0.72,P=0.15)和肺栓塞(OR 0.48,P=0.10)无显著差异。
  • 亚组分析中抗Xa指导的剂量调整未显著减少VTE(OR 0.68,P=0.08)。

适用人群与场景

  • 创伤患者,研究评估低分子肝素化学预防并报告抗Xa水平。

诊断标准与关键阈值

  • 抗Xa达标定义:峰值≥0.2 IU/mL或谷值≥0.1 IU/mL。

研究设计与关键结果

  • 系统检索MEDLINE、Embase、Scopus和Web of Science(2021年5月),纳入24项研究(19项回顾性、5项前瞻性)。
  • 分析1:抗Xa达标与VTE风险降低相关(VTE发生率4.0% vs 3.1%;OR 0.52;P=0.03)。
  • 分析2:剂量调整方案中768例(75.3%)患者达到预防性抗Xa水平。
  • 分析3:剂量调整较标准剂量提高抗Xa达标率(OR 4.05;P=0.007),但VTE(OR 0.72;P=0.15)和肺栓塞(OR 0.48;P=0.10)无显著差异。
  • 亚组分析:抗Xa指导的剂量调整未显著减少VTE(OR 0.68;P=0.08)。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,证据等级Level IV。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 创伤患者预防性低分子肝素后抗Xa水平较高者VTE风险较低。
  • 抗Xa指导的剂量调整可提高抗Xa达标率,但可能不减少VTE。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Trauma patients have simultaneously high venous thromboembolism (VTE) and bleeding risk. Optimal chemoprophylaxis regimens remain unclear. This study aims to answer three questions for trauma patients. Is there any association between anti-Xa and VTE? Does dose adjustment improve prophylactic anti-Xa rates? Does dose adjustment improve anti-Xa adequacy and VTE compared with standard dosing?

METHODS: Systematic search of MEDLINE, Embase, Scopus, and Web of Science occurred in May 2021. Two author reviews included trauma studies that evaluated low molecular weight heparin chemoprophylaxis, reported anti-Xa level, and evaluated more than one outcome. Data were dually extracted and estimated effects were calculated using RevMan 5.4 applying the Mantel-Haenszel method. Analysis 1 compared patients with peak anti-Xa of 0.2 IU/mL or greater or trough 0.1 IU/mL or greater to those with lower anti-Xa using VTE as the primary outcome. Analysis 2 reported the effect of dose adjustment on anti-Xa. Analysis 3 compared standard dosing to dose adjustment with the primary outcome being anti-Xa adequacy; secondary outcomes were VTE, pulmonary embolism, and bleeding complications.

RESULTS: There were 3,401 studies evaluated with 24 being included (19 retrospective studies, 5 prospective studies). In analysis 1, achieving adequate anti-Xa was associated with reduced odds of VTE (4.0% to 3.1%; odds ratio [OR], 0.52; p = 0.03). Analysis 2 demonstrated that 768 (75.3%) patients achieved prophylactic anti-Xa with adjustment protocols. Analysis 3 suggested that dose-adjusted chemoprophylaxis achieves prophylactic anti-Xa more frequently (OR, 4.05; p = 0.007) but without VTE (OR, 0.72; p = 0.15) or pulmonary embolism (OR, 0.48; p = 0.10) differences. In subgroup analysis, anti-Xa dose adjustment also suggested no VTE reduction (OR, 0.68; p = 0.08).

CONCLUSION: Patients with higher anti-Xa levels are less likely to experience VTE, and anti-Xa guided chemoprophylaxis increases anti-Xa adequacy. However, dose adjustment, including anti-Xa guided dosing, may not reduce VTE.

LEVEL OF EVIDENCE: Systematic Review Meta-Analysis, Level IV.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Verhoeff K, Raffael K, Connell M, et al. Relationship between anti-Xa level achieved with prophylactic low-molecular weight heparin and venous thromboembolism in trauma patients: A systematic review and meta-analysis. J Trauma Acute Care Surg. 2022. PMID: 35195094. doi:10.1097/TA.0000000000003580

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。